CereVasc announced today that it completed the first treatment with its eShunt system for treating communicating hydrocephalus (CH).
Boston-based CereVasc touts the eShunt as the first minimally invasive cerebrospinal fluid shunt and delivery technology designed to avoid the need for invasive surgery and extended hospitalization associated with the current surgical treatment of hydrocephalus.
The company said in a news release that it designed the eShunt to offer improvements compared to the current treatment, a half-century-old neurosurgical procedure that is associated with frequent failure, infection risk and high costs.
Dr. Pedro Lylyk reported the first case as he conducts the first-in-human study of the eShunt system at Clinica la Sagrada Familia in Buenos Aires, Argentina. The ongoing trial will produce additional data in 2022, CereVasc said.
“Despite this being very early data, there is great significance in the first-ever treatment of hydrocephalus using a minimally invasive approach,” CereVasc Chairman & CEO Dan Levangie said in the release.
Dr. Adel Malek, Chief of Neurovascular Surgery, Tufts Medical Center, Boston, Massachusetts, inventor and co-founder of CereVasc added, “We are very pleased to have JNIS publish the first patient case report. The details and outcome of this case are encouraging signs about the potential of the eShunt System to address a common neurological condition with a long history of poor treatment options.”